Biocept, Inc. Stock price

Equities

BIOCQ

US09072V6002

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets 10:55:54 2024-03-25 am EDT 5-day change 1st Jan Change
0.0001 USD +9,900.00% Intraday chart for Biocept, Inc. 0.00% -99.76%
Sales 2021 61.25M Sales 2022 25.86M Capitalization 9.04M
Net income 2021 -2M Net income 2022 -32M EV / Sales 2021 0.73 x
Net cash position 2021 16.19M Net cash position 2022 788K EV / Sales 2022 0.32 x
P/E ratio 2021
-18.9 x
P/E ratio 2022
-0.28 x
Employees 50
Yield 2021 *
-
Yield 2022
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Biocept, Inc.

1 day+9,900.00%
3 months-99.75%
6 months-99.99%
Current year-99.76%
More quotes
1 week
0.00
Extreme 0.0001
0.00
1 month
0.00
Extreme 0
0.13
Current year
0.00
Extreme 0
0.13
1 year
0.00
Extreme 0
13.43
3 years
0.00
Extreme 0
192.00
5 years
0.00
Extreme 0
633.00
10 years
0.00
Extreme 0
216 000.22
More quotes
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer - 19-12-31
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer 60 22-03-07
More insiders
Date Price Change Volume

Delayed Quote OTC Markets, March 25, 2024 at 10:55 am EDT

More quotes
Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular technologies intended to aid medical professionals in CSF analysis and central nervous system (CNS) disease management in patients with solid tumors. It offers and conducts its commercialized diagnostic assays, which include cell capture and enumeration, immunocytochemistry, fluorescent in situ hybridization (FISH), and next generation sequencing (NGS). It has commercialized its CNSide assays for detecting and characterizing many different carcinomas and melanoma. These assays utilize its dual cellular and ctDNA technology platforms and provide biomarker analysis from a patient's CSF sample.
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0001
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock Biocept, Inc. - OTC Markets